| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| ArriVent BioPharma, Inc. | President and CEO, Director | Stock Option (right to buy) | 550,000 | 02 Feb 2026 | Direct | ||
| ALUMIS INC. | Director | Stock Option (Right to Buy) | 49,800 | 30 Jul 2025 | Direct | ||
| NexImmune, Inc. | Director | Stock Option (right to buy) | 44,983 | 05 Jul 2023 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| AVBP | ArriVent BioPharma, Inc. | 02 Feb 2026 | 1 | $0 | 4 | President and CEO, Director | 04 Feb 2026, 20:40 |
| ALMS | ALUMIS INC. | 30 Jul 2025 | 1 | $0 | 4 | Director | 01 Aug 2025, 16:05 |
| AVBP | ArriVent BioPharma, Inc. | 03 Feb 2025 | 1 | $0 | 4 | President and CEO, Director | 14 Feb 2025, 16:27 |
| ALMS | ALUMIS INC. | 27 Jun 2024 | 7 | $0 | 4 | Director | 01 Jul 2024, 16:42 |
| ALMS | ALUMIS INC. | 27 Jun 2024 | 0 | $0 | 3 | Director | 27 Jun 2024, 16:11 |
| AVBP | ArriVent Biopharma, Inc. | 25 Jan 2024 | 0 | $0 | 3 | President and CEO, Director | 25 Jan 2024, 20:39 |
| /report/000095017023032252-yao-zhengbin-2023-07-05 | NexImmune, Inc. | 05 Jul 2023 | 1 | $0 | 4 | Director | 07 Jul 2023, 16:20 |
| /report/000120919123023684-yao-zhengbin-2023-04-04 | NexImmune, Inc. | 04 Apr 2023 | 6 | $0 | 4 | Director | 06 Apr 2023, 20:37 |
| /report/000120919122037006-yao-zhengbin-2022-06-13 | NexImmune, Inc. | 13 Jun 2022 | 1 | $0 | 4 | Director | 15 Jun 2022, 16:57 |